Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle University Trust Hospitals, Newcastle-Upon-Tyne, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK.
Ann Surg Oncol. 2021 Sep;28(9):4905-4915. doi: 10.1245/s10434-021-09720-6. Epub 2021 Mar 3.
Esophagectomy is a key component in the curative treatment of esophageal cancer. Little is understood about the impact of smoking status on perioperative morbidity and mortality and the long-term outcome of patients following esophagectomy.
This study aimed to evaluate morbidity and mortality according to smoking status in patients undergoing esophagectomy for esophageal cancer.
Consecutive patients undergoing two-stage transthoracic esophagectomy (TTE) for esophageal cancers (adenocarcinoma or squamous cell carcinoma) between January 1997 and December 2016 at the Northern Oesophagogastric Unit were included from a prospectively maintained database. The main explanatory variable was smoking status, defined as current smoker, ex-smoker, and non-smoker. The primary outcome was overall survival (OS), while secondary outcomes included perioperative complications (overall, anastomotic leaks, and pulmonary complications) and survival (cancer-specific survival [CSS], recurrence-free survival [RFS]).
During the study period, 1168 patients underwent esophagectomy for cancer. Of these, 24% (n = 282) were current smokers and only 30% (n = 356) had never smoked. The median OS of current smokers was significantly shorter than ex-smokers and non-smokers (median 36 vs. 42 vs. 48 months; p = 0.015). However, on adjusted analysis, there was no significant difference in long-term OS between smoking status in the entire cohort. The overall complication rates were significantly higher with current smokers compared with ex-smokers or non-smokers (73% vs. 66% vs. 62%; p = 0.018), and there were no significant differences in anastomotic leaks and pulmonary complications between the groups. On subgroup analysis by receipt of neoadjuvant therapy and tumor histology, smoking status did not impact long-term survival in adjusted multivariable analyses.
Although smoking is associated with higher rates of short-term perioperative morbidity, it does not affect long-term OS, CSS, and RFS following esophagectomy for esophageal cancer. Therefore, implementation of perioperative pathways to optimize patients may help reduce the risk of complications.
食管癌切除术是癌症治疗的重要组成部分。对于吸烟状况对食管癌切除术围手术期发病率和死亡率以及术后长期结果的影响,人们知之甚少。
本研究旨在评估吸烟状况与接受食管癌切除术患者的发病率和死亡率的关系。
从 1997 年 1 月至 2016 年 12 月在北方食管胃单位接受两阶段经胸食管癌切除术(TTE)的连续患者中纳入了一个前瞻性维护的数据库。主要解释变量为吸烟状况,定义为当前吸烟者、前吸烟者和非吸烟者。主要结果是总体生存率(OS),次要结果包括围手术期并发症(总体、吻合口漏和肺部并发症)和生存率(癌症特异性生存率 [CSS]、无复发生存率 [RFS])。
在研究期间,1168 例患者因癌症接受了食管癌切除术。其中,24%(n=282)为当前吸烟者,只有 30%(n=356)从未吸烟。当前吸烟者的中位 OS 明显短于前吸烟者和非吸烟者(中位数分别为 36、42 和 48 个月;p=0.015)。然而,在调整分析中,整个队列中吸烟状况与长期 OS 之间无显著差异。当前吸烟者的总体并发症发生率明显高于前吸烟者或非吸烟者(73%比 66%比 62%;p=0.018),各组之间吻合口漏和肺部并发症无显著差异。在接受新辅助治疗和肿瘤组织学的亚组分析中,吸烟状况在调整后的多变量分析中并未影响长期生存。
尽管吸烟与短期围手术期发病率较高相关,但不会影响食管癌切除术的长期 OS、CSS 和 RFS。因此,实施围手术期途径以优化患者可能有助于降低并发症风险。